Nasdaq · CIK 0001719406
NRXP NRX Pharmaceuticals, Inc.
Insider trading from SEC Form 4. Last filing Feb 17, 2026. Close $2.85 on Oct 9, 2026, +70% from the 52-week low and -38% from the high.
NRX Pharmaceuticals, Inc. (NRXP) has 7 SEC Form 4 filings on file from 6 insiders, the latest filed on Feb 17, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
1 open-market trade has been scored at NRXP. The newest: Jonathan C Javitt (Chairman and Chief Scientist) bought $47k of stock on Dec 17, 2024, filed Dec 18, 2024, scored 36 (weak).
NRXP closed at $2.85 on Oct 9, 2026, 70% above its 52-week low and 38% below its 52-week high.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at NRX Pharmaceuticals, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 36Weak | Jonathan C Javitt Chairman and Chief Scientist buy | $47k 40,000 shares | +90% | - |
Transactions
Every row filed, 7 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 27, 2026 | Joseph Michael Casper Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Feb 17, 2026 |
| Apr 9, 2025 | Patrick John Flynn director | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Sep 10, 2025 |
| Apr 9, 2025 | Chaim Hurvitz director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Sep 10, 2025 |
| Apr 9, 2025 | Jonathan C Javitt Chairman and Chief Scientist | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | Sep 10, 2025 |
| Apr 9, 2025 | Dennis McBride director | AGrant or award Stock Option (right to buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Sep 10, 2025 |
| Feb 7, 2025 | Michael S Abrams Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +50,000 | $0.00 | $0 | 50,000 | Feb 11, 2025 |
| Dec 17, 2024 | Jonathan C Javitt Chairman and Chief Scientist | POpen-market purchase Common Stock | +40,000 | $1.17 | $47k | 84,634 | Dec 18, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Michael S AbramsChief Financial Officer
- Joseph Michael CasperChief Operating Officer
- Patrick John Flynndirector
- Chaim Hurvitzdirector
- Jonathan C JavittChairman and Chief Scientist
- Dennis McBridedirector
Questions about NRXP
Answered from the filings on this page, as of the latest one.
Are insiders buying NRXP?
No. In the last 90 days no insider at NRX Pharmaceuticals, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade NRXP on the open market?
Jonathan C Javitt (Chairman and Chief Scientist) bought $47k of NRXP on Dec 17, 2024 and filed the Form 4 on Dec 18, 2024. InsiderTell scored 36 (weak).
How many insiders file Form 4 at NRX Pharmaceuticals, Inc.?
6 people have filed a Form 4 at NRX Pharmaceuticals, Inc., among them Michael S Abrams (Chief Financial Officer), Joseph Michael Casper (Chief Operating Officer), Patrick John Flynn (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.